R M Aly1, H F Ghazy. 1. Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Abstract
INTRODUCTION: The Musashi-2 gene (MSI2) is implicated in leukemogenesis, and high MSI2 expression has been associated with decreased survival in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), suggesting its use as a new prognostic marker. We aimed to validate the prognostic significance of MSI2 in ALL. METHODS: MSI2 expression was measured by real-time polymerase chain reaction in 140 adult B-ALL patients and compared to controls. RESULTS: MSI2 expression level in patients was significantly higher when compared to the control group (P = 0.001). High MSI2 expression did not correlate with the clinical characteristics of patients. However, patients with high MSI2 expression had significantly lower incidence of complete remission (CR) (P = 0.03), inferior overall survival (P = 0.018), and shorter disease-free survival (P = 0.001). Multivariate analysis revealed that high MSI2 expression was an independent prognostic factor for adult BCR-ABL1-negative B-ALL patients. CONCLUSION: These results confirm the association of MSI2 expression with outcome in adult B-ALL and demonstrate the utility of MSI2 as a clinical prognostic biomarker.
INTRODUCTION: The Musashi-2 gene (MSI2) is implicated in leukemogenesis, and high MSI2 expression has been associated with decreased survival in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), suggesting its use as a new prognostic marker. We aimed to validate the prognostic significance of MSI2 in ALL. METHODS:MSI2 expression was measured by real-time polymerase chain reaction in 140 adult B-ALL patients and compared to controls. RESULTS:MSI2 expression level in patients was significantly higher when compared to the control group (P = 0.001). High MSI2 expression did not correlate with the clinical characteristics of patients. However, patients with high MSI2 expression had significantly lower incidence of complete remission (CR) (P = 0.03), inferior overall survival (P = 0.018), and shorter disease-free survival (P = 0.001). Multivariate analysis revealed that high MSI2 expression was an independent prognostic factor for adult BCR-ABL1-negative B-ALL patients. CONCLUSION: These results confirm the association of MSI2 expression with outcome in adult B-ALL and demonstrate the utility of MSI2 as a clinical prognostic biomarker.
Authors: Sujitha Duggimpudi; Andreas Kloetgen; Sathish Kumar Maney; Philipp C Münch; Kebria Hezaveh; Hamed Shaykhalishahi; Wolfgang Hoyer; Alice C McHardy; Philipp A Lang; Arndt Borkhardt; Jessica I Hoell Journal: J Biol Chem Date: 2018-08-20 Impact factor: 5.157
Authors: Lan Lan; Hao Liu; Amber R Smith; Carl Appelman; Jia Yu; Sarah Larsen; Rebecca T Marquez; Xiaoqing Wu; Frank Y Liu; Philip Gao; Ragul Gowthaman; John Karanicolas; Roberto N De Guzman; Steven Rogers; Jeffrey Aubé; Kristi L Neufeld; Liang Xu Journal: BMC Cancer Date: 2018-08-10 Impact factor: 4.430
Authors: Lan Lan; Minli Xing; Maithri Kashipathy; Justin Douglas; Philip Gao; Kevin Battaile; Robert Hanzlik; Scott Lovell; Liang Xu Journal: Proteins Date: 2019-10-29
Authors: Leonid Kharin; Igor Bychkov; Nikolay Karnaukhov; Mark Voloshin; Rushaniya Fazliyeva; Alexander Deneka; Elena Frantsiyants; Oleg Kit; Erica Golemis; Yanis Boumber Journal: PLoS One Date: 2021-07-08 Impact factor: 3.240